OCTAPHARMA
Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017 as an Early View article in the internationally renowned medical journal, Haemophilia .
The NuPreviq study was initiated in August 2013 with the aim of developing a fully personalized service for HA patients undergoing prophylactic therapy. Octapharma’s aim is to improve patient treatment experiences by recognizing that no two HA patients are the same, therefore a “one size fits all ” approach to prophylaxis is not ideal. The NuPreviq study investigated a novel approach, allowing the Nuwiq® treatment regimen to be adapted to the specific needs of each individual patient. The NuPreviq Approach measures and profiles each individual patient’s pharmacokinetic response to treatment, which then allows the dosing of Nuwiq® to be personalized according to the specific circumstances of that patient.
The results of the study showed that this personalized prophylaxis approach was very effective at preventing bleeds, while reducing the frequency of dosing and the amount of Nuwiq® needed. Over 80% of patients did not experience a spontaneous bleed during the 6 months of personalized prophylaxis with Nuwiq® . More than half of the patients received infusions twice a week or less, and dose requirements were reduced by 7%. An ongoing extension study (GENA-21b, NCT02256917) will further evaluate the long-term efficacy and safety of personalized prophylaxis with Nuwiq® .
Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results of the NuPreviq study and pleased that the GENA-21 study data are now available to the wider public in the specialist peer-reviewed publication, Haemophilia. The study shows that personalized prophylaxis with Nuwiq ® provides excellent bleeding protection, extension of the dosing interval for most patients, and a reduction in dose. These data further differentiate Nuwiq ® from other products on the market.”
Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s principal motivation lies with providing dedicated service to our patients. Developing a custom care package which offers flexible FVIII therapy , truly personalized to suit their needs and lifestyle, has long been a goal of the company and we celebrate today this landmark publication of the extremely positive NuPreviq clinical data.”
Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible.
About GENA-21 and GENA-21b studies: The GENA-21 and GENA-21b studies, initiated in August 2013 and March 2015, respectively, are prospective, open-label, multicentre, Phase 3b studies assessing the safety and efficacy of PK-guided personalized prophylaxis with Nuwiq® in previously treated adult patients with severe HA. The studies are each conducted across 29 study locations worldwide.
About Nuwiq ® : Nuwiq® is a naturally long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs (190 individuals) with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.
About haemophilia A: Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralizing FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.
About Octapharma :
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005497/en/
Contact:
Octapharma AG
International Business Unit - Haematology
Olaf
Walter
Olaf.Walter@octapharma.com
or
Larisa
Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel:
+41 55 4512121
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Megaport Surpasses 1,000 Enabled Locations Worldwide7.8.2025 22:00:00 CEST | Press release
Megaport now provides access from 10% of all data centres worldwide, making it the world’s leading Network as a Service provider. Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, announced today that it has launched its 1,000th Megaport-enabled location. With this milestone, Megaport now provides access from 10% of all public data centres worldwide, making it the world’s leading vendor-neutral NaaS connectivity platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250807394677/en/ With over 1,000 enabled locations, Megaport now provides access from 10% of all data centres worldwide. From its start as a disruptor in the connectivity space, Megaport has now become the go-to solution for IT teams needing fast, flexible, and secure interconnection between cloud services, data centres, and enterprise sites. The Company’s global reach now spans over 160 cities across 26 countrie
Andersen Consulting indgår samarbejdsaftale med Systematix7.8.2025 21:38:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation og cybersikkerhed med tilføjelsen af samarbejdspartneren Systematix, et førende teknologikonsulentfirma, der er kendt for at levere innovative digitale løsninger, der bidrager til operationel effektivitet, vækst og konkurrencemæssige fordele. Systematix blev stiftet i 1975 og tilbyder komplette konsulent- og implementeringstjenester inden for digital transformation, udvikling af virksomhedsapplikationer, ERP, forretningsanalyse, it-strategi og cybersikkerhed. Med hundredvis af erfarne konsulenter og teknologer hjælper Systematix deres kunder med at navigere i komplekse forretningsmæssige udfordringer ved hjælp af nye teknologier og tilbyder skalerbare løsninger til en række robuste brancher, herunder finanssektoren, sundhedsvæsenet, produktionsvirksomheder og organisationer i den offentlige sektor. "I de sidste fem årtier har vi opbygget et omdømme for at levere robuste teknologiløsninger og ressourcer, der h
Lyten to Acquire All Remaining Northvolt Assets in Sweden and Germany7.8.2025 18:24:00 CEST | Press release
Lyten, the global leader in lithium-sulfur batteries, announced it has entered into binding agreements to acquire Northvolt Ett and Ett Expansion, Northvolt Labs, Northvolt Drei, and all remaining Northvolt intellectual property (IP). These newly acquired assets were previously valued at approximately $5B and include 16 GWh of operational battery production capacity and over 15 GWh under construction. Lyten has expressed interest in additionally acquiring Northvolt Six in Quebec, Canada. Lyten plans to restart operations at Northvolt Ett and Northvolt Labs upon close of the transaction, which is being fully funded with equity investment. Lyten, the global leader in lithium-sulfur batteries, announced today that it has entered into a binding agreement to acquire Northvolt’s remaining assets in Sweden and Germany. The acquisition includes Northvolt Ett and Ett Expansion (Skellefteå, Sweden), Northvolt Labs (Västerås, Sweden), and Northvolt Drei (Heide, Germany). Additionally, Lyten is ac
Energy Vault Secures Final FIRB Approval and Completes Acquisition of 125 MW/1,000 MWh Stoney Creek BESS in Australia7.8.2025 15:15:00 CEST | Press release
Stoney Creek represents first acquisition in Australia as part of Energy Vault’s global “Own & Operate” portfolio and reinforces long-term commitment to Australia’s energy transition125 MW/1,000 MWh Stoney Creek BESS set to support grid reliability and flexibility while advancing the energy transition in New South Wales, supported by a 14-year offtake agreementStoney Creek is Energy Vault’s third and largest Energy Storage Asset in the portfolio, following the successful completion of the Cross Trails BESS in Texas and Calistoga Resiliency Center in California, and is expected to deliver ~$30 million in combined annual, recurring EBITDA for the next 15+ years Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in grid-scale energy storage solutions, today announced it has received Foreign Investment Review Board (FIRB) approval and completed the full acquisition of the Stoney Creek Battery Energy Storage System (BESS) project in Northern New South Wales. The 125
Museum Centre Vapriikki:Ancient DNA Reveals 800-year-old Family Link in Medieval Finland7.8.2025 14:05:00 CEST | Press release
Ancient DNA research led by the Museum Centre Vapriikki in Tampere, Finland, in collaboration with the universities of Turku and Helsinki, has produced new insights into kinship, health, and population continuity in medieval and early modern Finland. Published in the peer-reviewed journal iScience, the research presents results from 25 individuals in Finland – a significant result in a country where acidic soils often lead to poor preservation of bones and genetic material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250807066724/en/ The woman’s grave in Vilusenharju, Tampere was discovered in 1962, and the man’s grave in Ristiänmäki, Pälkäne in 1982. Ancient DNA research has now revealed that the deceased were siblings. Illustrations by Veronika Paschenko. Photo by Vapriikki. Researchers successfully recovered DNA from individuals buried between the 12th and 19th centuries at three cemeteries in the Tampere region. The s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom